Claret Medical
1745 Copperhill Parkway
Suite 1
Santa Rosa
California
95403
United States
Tel: 707-528-9300
Fax: 707-528-9302
Website: http://www.claretmedical.com/
Email: info@claretmedical.com
18 articles about Claret Medical
-
Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.
-
Updated: Boston Scientific Continues M&A Spree with $160 Million Deal for Veniti; Lays Off 85 in ...
8/8/2018
Two days after Boston Scientific laid off 85 employees at a Burlington, Mass. manufacturing site, the company forked over up to $160 million to acquire California stent maker Veniti, Inc. The deal marks the third acquisition for Boston Scientific in two months. -
Boston Scientific Closes Acquisition of Claret Medical, Inc., Announces Positive Reimbursement Decision
8/2/2018
CMS Grants NTAP Designation for The Sentinel® Cerebral Protection System
-
Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.
7/20/2018
Addition of FDA-cleared Sentinel® Cerebral Embolic Protection System to Expand Company's Structural Heart Offerings
-
Claret Medical’s Sentinel Cerebral Protection System Emerging as U.S. Standard of Care for Protecting the Brain from Risk of Stroke During Transcatheter Aortic Heart Valve Replacement
2/14/2018
The novel system, which has been shown to significantly reduce the risk of stroke in the first three days after TAVR by more than 60 percent, has been adopted by 50 U.S. centers as part of its controlled rollout.
-
Bay Area's Claret Medical Nabs $14.5M
10/23/2017
The investment was led by Lightstone Ventures, with participation from existing investors Easton Capital, HealthCor Partners, Incept LLC and Sante Ventures. -
Claret Medical Release: Sentinel Cerebral Protection System Used Commercially By TAVR Centers Of Excellence Nationwide
6/16/2017
-
Bay Area's Claret Medical Wins FDA Nod to Market Sentinel Cerebral Protection System in the U.S.
6/5/2017
-
Claret Medical Release: FDA Advisory Committee Strongly Supports Granting De Novo Application For The First Cerebral Protection System For Transcatheter Aortic Valve Replacement (TAVR)
2/27/2017
-
Claret Medical Release: Results From U.S. Pivotal IDE Trial Show That Sentinel Cerebral Protection System Protects Patients During Transcatheter Aortic Valve Replacement
11/1/2016
-
Claret Medical Submits Marketing Application To FDA For US Clearance Of First Cerebral Protection System For Transcatheter Aortic Valve Replacement (TAVR)
9/20/2016
-
Claret Medical Announces Sentinel Pivotal IDE Trial To Be Featured In Late-Breaking Trial Session At Transcatheter Cardiovascular Therapeutics (TCT) Conference
9/14/2016
-
Claret Medical Release: New Study Shows Definitive Neurocognitive Benefit For Patients Protected By Sentinel Cerebral Protection System During Transcatheter Aortic Valve Replacement (TAVR)
10/15/2015
-
Claret Medical Announces First Patient Treated In U.S. Pivotal Trial Evaluating Cerebral Protection During Transcatheter Aortic Valve Replacement (TAVR)
10/6/2014
-
CLEAN-TAVI Trial Shows Claret Medical Cerebral Protection System Dramatically Reduces Brain Lesions And Neurological Events Following Transcatheter Aortic Valve Replacement (TAVR)
9/15/2014
-
Claret Medical Release: Patient Enrollment Completed In Landmark CLEAN-TAVI Clinical Trial Studying The Role Of Cerebral Protection In Reducing Cerebrovascular Events
9/4/2014
-
California Device Maker Claret Medical Chases FDA Win With $18 Million Series B For Cerebral Protection Device
8/22/2014
-
Claret Medical Announces IDE Approval For U.S. Pivotal Trial Of The Sentinel Cerebral Protection System
2/18/2014